



# BERYL DRUGS LIMITED

**Regd. Off.:** Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

**Tel. :** (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

**Date:** 3<sup>rd</sup> September, 2020

To,

The Secretary,  
Department of Corporate Services,  
Bombay Stock Exchange Limited (BSE),  
Phiroze Jeejeebhoy Towers, Dalal Street,  
Mumbai – 400001

**Scrip Code:** 524606

**Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its Board Meeting held on 03.09:2020 has approved the Unaudited Financial Results of the Company for the Quarter ended 30<sup>th</sup> June, 2020.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited

  


**Sudhir Sethi**  
Chairman & Director  
DIN: 00090172



**BERYL DRUGS LIMITED**  
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.  
Tel./ Fax 0731-2517677  
E-mail : beryldrugs25@yahoo.com

**ANNEXURE I**

**Part I Submission of Unaudited/ Audited Financial Result by Companies Other than Banks**

**Statement of standalone Unaudited Result for the Quarter/year ended 30/06/2020**

(Rs In 000)

Particulars	Quarter ended			Year ended
	3 months ended (30.06.2020)	Preceding 3 months ended (31.03.2020)	Corresponding 3 months ended in the previous year (30-06-2019)	Previous year ended (31-03-2020)
	Unaudited	Audited	Unaudited	Audited
<b>1 Revenue From Operations</b>				
Net sales or Revenue from Operations				
Other operating revenues	26965.000	30607.000	42303.000	128151.000
<b>Total Revenue from operations (net)</b>	51.000	492.000	27.000	2331.000
<b>2 Expenses</b>	27016.000	31099.000	42330.000	130482.000
(a) Cost of materials consumed				
(b) Purchases of stock-in-trade	16399.000	16822.000	20350.000	66779.000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.000	0.000	0.000	0.000
(d) Employee benefit expense	-2437.000	3078.000	960.000	-700.000
(e) Finance costs	2514.000	2600.000	1978.000	9653.000
(f) Depreciation and amortisation expense	1381.000	1385.000	986.000	3210.000
(g) Other Expenses	3459.000	2504.000	1045.000	6594.000
<b>Total expenses</b>	7441.000	10876.000	13160.000	43367.000
<b>3 Profit (loss) from operations before exceptional and extraordinary items and tax</b>	28757.000	37265.000	38479.000	128903.000
<b>4 Exceptional items</b>	-1741.000	-6166.000	3851.000	1579.000
<b>5 profit (loss) before extraordinary items and tax</b>	0.000	0.000	0.000	0.000
<b>6 Extraordinary items</b>	-1741.000	-6166.000	3851.000	1579.000
<b>7 Profit (loss) before tax</b>	0.000	0.000	0.000	0.000
<b>8 Tax Expense</b>	-1741.000	-6166.000	3851.000	1579.000
Current tax				
Deferred tax	0.000	-1655.000	600.000	-355.000
<b>Total Tax Expenses</b>	219.000	705.000	-175.000	1455.000
<b>9 Net Profit (loss) for the period from continuing operations</b>	219.000	-950.000	425.000	1100.000
<b>10 Net Profit (loss) from discontinuing operations before tax</b>	-1960.000	-5216.000	3426.000	479.000
<b>11 Tax Expense of discontinuing operations</b>	0.000	0.000	0.000	0.000
<b>12 Net Profit (loss) from discontinuing operations after tax</b>	0.000	0.000	0.000	0.000
<b>13 Net Profit (loss) for the Period</b>	0.000	0.000	0.000	0.000
<b>14 Other comprehensive Income</b>	-1960.000	-5216.000	3426.000	479.000
<b>15 Total Comprehensive Income</b>	-634.000	627.000	-82.000	494.000
<b>16 Details of equity share capital</b>	-2594.000	-4589.000	3344.000	973.000
Paid-up equity share capital				
Face value of equity share capital	50717.000	50717.000	50717.000	50717.000
<b>17 Earnings per share</b>	10.000	10.000	10.000	10.000
i Basic earnings per share before extraordinary items				
ii Diluted earnings per share before extraordinary items	-0.390	-1.030	0.680	0.090
	-0.390	-1.030	0.680	0.090

Notes:

- The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- The above results for the quarter ended 30th June 2020 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 3rd September, 2020 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- The figures for the quarter ended March 31, 2020 are balancing figures between audited figures in respect of full financial year ended March 31, 2020 and the unaudited published figure up to December 31, 2019 being the end of third quarter of the financial year which were subjected to limited review.
- The Company is not much affected due to lockdown due to COVID-19. The Company is dealing in manufacturing of Drugs and medicines which falls in essential commodities hence duly permitted by local administration to work even during lockdown. However, the sales during the quarter falls due to low demand. But the management does not foresee any material impact on its business due to COVID-19.
- The figures for the previous periods have been regrouped, wherever necessary.
- Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.
- Earnings per Share amount is Shown in Rupees.

Place : Indore  
Date : 03.09.2020

  
Director  
For and behalf of the Board  
  
Sanjay Sethi  
Managing Director

# PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: [caprateekjain@gmail.com](mailto:caprateekjain@gmail.com)



## LIMITED REVIEW REPORT

To,

The Board of Directors

**Beryl Drugs Limited**

133, Kanchan Bagh,

Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** ("the Company") for the quarter ended **30<sup>th</sup> June, 2020** attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR PRATEEK JAIN AND CO.  
CHARTERED ACCOUNTANTS  
FRN-009494C**



*Prateek Jain*

**PRATEEK JAIN  
PROPRIETOR  
M. No. 079214**

**Date: 3<sup>rd</sup> September, 2020**

**Place: Indore**

**UDIN: 20079214AAAAABE4050**